Yahoo FinanceApr 15, 2026
Verismo Therapeutics Announces $28 Million Investment from HLB Innovation to Accelerate KIR-CAR Clinical Development
Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology, today announced a $28 million investment from its parent company, HLB Innovation (KOSDAQ: 024850). The investment comes ahead of a significant clinical milestone: the first-ever presentation of KIR-CAR clinical data, which will be featured in the Late-Breaking Clinical Trials plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San